Results 61 to 70 of about 5,684 (155)

Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database

Patient Preference and Adherence, 2022
Anuja Roy,1 Andrew Peterson,2 Nick Marchant,1 Jose Alvir,3 Rahul Bhambri,4 Jason Lynn,4 Darrin Benjumea,5 Sapna Prasad,6 Alex O’Brien,6 Yong Chen,7 Jason Kemner,8 Bhash Parasuraman8 1Global HEOR, Patient & Health Impact, Rare Diseases BU, Pfizer Inc, New
Roy A, Peterson A, Marchant N, Alvir J, Bhambri R, Lynn J, Benjumea D, Prasad S, O'Brien A, Chen Y, Kemner J, Parasuraman B   +11 more
doaj  

Systemic Amyloidosis With Probable Cardiac Involvement: Diagnostic Approach in a Resource‐Limited Setting: A Case Report

Clinical Case Reports, Volume 14, Issue 7, July 2026.
Histopathological examination of an abdominal fat pad core needle biopsy demonstrating Congo red–positive amyloid deposition, confirming systemic amyloidosis. Representative photomicrographs illustrate characteristic amyloid deposits at low‐ and high‐power magnification.
Malegna Temesgen Garuma, Yonatan Debebe Regassa, Sifessa Dessalegn Demshasha   +2 more
wiley   +1 more source

Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)

Cardiology and Therapy
Introduction Tafamidis is the first drug approved by the European Commission for the treatment of wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related ...
Sepideh Attal, Jason Kemner, Jose Alvir, Sebastian Barth, Sofia Schuessler   +4 more
doaj   +1 more source

Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients

Muscle &Nerve, Volume 73, Issue 6, Page 1118-1127, June 2026.
This exploratory analysis of data from the NEURO‐TTRansform trial evaluated sex‐specific responses in patients with ATTRv‐PN who had received eplontersen in NEURO‐TTRansform versus a historical placebo. Eplontersen can lead to substantial decreases in percentage serum TTR levels, arrest neuropathy impairment, and improve patient quality of life ...
Márcia Waddington Cruz, John L. Berk, Yeşim Parman, Morie Gertz, Sami Khella, Markus Weiler, T. Jesse Kwoh, Maksym Pola, Barry Reicher, Jonatan Nåtman, Noel R. Dasgupta, Jonas Wixner   +11 more
wiley   +1 more source

Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary

, 2023
This summary presents the results from an ongoing, long-term extension study that followed an earlier study called ATTR-ACT. People who took part in this extension study and ATTR-ACT have a type of heart disease known as transthyretin amyloid ...
Sultan, Marla B, Elliott, Perry, Drachman, Brian M, Gundapaneni, Balarama, Lenihan, Daniel J, Hoffman, James E, Gottlieb, Stephen S, Li, Benjamin, Shah, Sanjiv J, Ebede, Ben, Hummel, Scott L, Perry Elliott, Balarama Gundapaneni, Daniel J Lenihan, Benjamin Li, Ben Ebede, James E Hoffman, Marla B Sultan, Brian M Drachman, Sanjiv J Shah, Stephen S Gottlieb, Scott L Hummel   +21 more
core   +1 more source

Early‐Onset Wild‐Type Transthyretin Amyloidosis Polyneuropathy

Muscle &Nerve, Volume 74, Issue 5, Page 1471-1475, November 2026.
Chafic Karam, Kaylee Baker, Sami Khella, Brian Drachman, Pranav Chandrashekar, MacLean Nasrallah, Shunsuke Koga, Janice Pieretti   +7 more
wiley   +1 more source

Redefining therapeutics in vATTR: Evaluation of response predictors to tafamidis and patisiran treatment in a non-endemic area. A proposal for a novel individualised therapeutic approach

Neurología
Introduction: Hereditary transthyretin amyloidosis (vATTR) is a progressive genetic disorder with several approved treatments. We investigated treatment responses to tafamidis and patisiran in vATTR patients to identify predictive response factors ...
L. Martínez-Vicente, V. Gajate-García, G. Gutiérrez-Gutiérrez, Á.L. Guerrero-Peral, A. Horga, A. Guerrero-Sola, J. Álvarez-Troncoso, M.A. Restrepo-Córdoba, J. Goirigolzarri-Artaza, S. Martín-Albarrán, A. Valverde-Megías, E. González-López, P. García-Pavía, J. Matías-Guiu, L. Galán-Dávila   +14 more
doaj   +1 more source

Benzofuran‐Based Uricosuric Agents: History, Roles, and Challenges

ChemistrySelect, Volume 11, Issue 24, 25 June 2026.
Benzofuran‐based uricosuric agents represent a privileged medicinal chemistry scaffold for gout therapy. Structural optimization of benzbromarone‐related derivatives has improved hURAT1 inhibitory potency, metabolic stability, and urate‐lowering efficacy, while reducing hepatotoxic liability.
Raed M. Al‐Zoubi, Basma Hanbali, Mai Elaarag, Zainab Fares, Enas A. Al‐Hurani, Sally R. Al‐Zoubi, Mohanad Shkoor, Abdelali Agouni   +7 more
wiley   +1 more source

Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.

, 2019
Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM). Data Sources: A PubMed (1966 to October 2019) and ClinicalTrials.
Andrews, Ebony, Ling, Hua, Ombengi, David, Park, Jonathan, Parker, Shanea, Egolum, Ugochukwu   +5 more
core   +1 more source

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy

Drug, Healthcare and Patient Safety, 2023
Catarina Falcão de Campos,1,2 Isabel Conceição1,2 1Department of Neurosciences and Mental Health, Centro Hospitalar Universitário de Lisboa-Norte, Lisbon, Portugal; 2Instituto de Fisiologia, Instituto de Medicina Molecular, Centro de Estudos Egas Moniz ...
Falcão de Campos C, Conceição I
doaj